Medtronic Neurovascular has announced the appointment of Adam Arthur as its chief medical officer, effective 30 September 2025.
A company press release states that Arthur brings more than 20 years of experience as a practising neurosurgeon, having previously served as chair of neurosurgery at the University of Tennessee Health Science Center (Memphis, USA). His leadership in clinical trials and commitment to innovation have driven improved outcomes for stroke patients and advanced the field of neurovascular care, the release adds.
“I’m excited and honoured to join the team at Medtronic Neurovascular as chief medical officer,” said Arthur. “My top priority is improving care for patients, and this role allows me to be closer to the innovations that will deliver better patient outcomes.”
In his new role, Arthur will guide clinical development strategy, strengthen relationships within the physician community, and further Medtronic’s commitment to continually improving patient outcomes. Arthur will also continue to devote a portion of his time to patient care through his practice at the Semmes-Murphey Clinic (Memphis, USA) and remain on the faculty at the University of Tennessee Health Science Center’s College of Medicine.
“It’s an exciting time to be a part of the neurovascular team as we focus on creating future breakthroughs in stroke care,” said Medtronic Neurovascular president Linnea Burman. “I’m confident Dr Arthur will play an important role in advancing our goal of helping more stroke patients access world-class neurovascular care.”
The recent release also notes that Arthur’s addition to Medtronic Neurovascular exemplifies the company’s founding principle: bringing clinical expertise to industry.
